Bray Capital Advisors Gilead Sciences, Inc. Transaction History

Bray Capital Advisors

$353 Million
Q4 2024

A detailed history of Bray Capital Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bray Capital Advisors holds 708 shares of GILD stock, worth $73,504. This represents 0.02% of its overall portfolio holdings.

Number of Shares

708

Previous 707 0.14%

Holding current value

$73,504

Previous $59,000 10.17%

% of portfolio

0.02%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 03, 2025	BUY	$83.95 - $97.9 $83 - $97	1 Added 0.14%	708 $65,000
Q3 2024 Nov 01, 2024	BUY	$66.59 - $83.99 $133 - $167	2 Added 0.28%	707 $59,000
Q2 2024 Jul 31, 2024	BUY	$63.15 - $72.88 $189 - $218	3 Added 0.43%	705 $48,000
Q1 2024 Apr 30, 2024	BUY	$71.58 - $87.29 $143 - $174	2 Added 0.29%	702 $51,000
Q4 2023 Jan 29, 2024	BUY	$73.27 - $83.09 $73 - $83	1 Added 0.14%	700 $56,000
Q3 2023 Oct 27, 2023	BUY	$73.94 - $80.67 $37,117 - $40,496	502 Added 254.82%	699 $52,000
Q2 2023 Jul 28, 2023	BUY	$76.01 - $86.7 $152 - $173	2 Added 1.03%	197 $15,000
Q1 2023 Apr 28, 2023	BUY	$77.31 - $88.08 $154 - $176	2 Added 1.04%	195 $16,000
Q4 2022 Jan 20, 2023	BUY	$62.32 - $89.47 $124 - $178	2 Added 1.05%	193 $0
Q3 2022 Nov 21, 2022	BUY	$59.54 - $68.01 $119 - $136	2 Added 1.06%	191 $12,000
Q2 2022 Aug 01, 2022	BUY	$57.72 - $65.01 $115 - $130	2 Added 1.07%	189 $12,000
Q1 2022 May 03, 2022	BUY	$57.92 - $72.58 $115 - $145	2 Added 1.08%	187 $11,000
Q4 2021 Jan 31, 2022	BUY	$64.88 - $73.64 $129 - $147	2 Added 1.09%	185 $13,000
Q3 2021 Oct 28, 2021	BUY	$67.69 - $73.03 $135 - $146	2 Added 1.1%	183 $13,000
Q2 2021 Jul 28, 2021	SELL	$63.47 - $69.35 $5,712 - $6,241	-90 Reduced 33.21%	181 $12,000
Q1 2021 May 03, 2021	BUY	$60.0 - $68.46 $120 - $136	2 Added 0.74%	271 $18,000
Q4 2020 Jan 28, 2021	BUY	$56.65 - $64.55 $5,325 - $6,067	94 Added 53.71%	269 $16,000
Q3 2020 Oct 30, 2020	BUY	$62.1 - $78.08 $124 - $156	2 Added 1.16%	175 $11,000
Q2 2020 Jul 28, 2020	BUY	$72.34 - $84.0 $72 - $84	1 Added 0.58%	173 $13,000
Q1 2020 May 01, 2020	BUY	$62.63 - $80.22 $125 - $160	2 Added 1.18%	172 $13,000
Q4 2019 Jan 31, 2020	BUY	$61.62 - $67.78 $61 - $67	1 Added 0.59%	170 $11,000
Q3 2019 Oct 29, 2019	SELL	$62.51 - $69.0 $166,776 - $184,092	-2,668 Reduced 94.04%	169 $11,000
Q2 2019 Jul 29, 2019	BUY	$61.87 - $69.38 $123 - $138	2 Added 0.07%	2,837 $192,000
Q1 2019 Apr 30, 2019	BUY	$62.53 - $70.05 $62 - $70	1 Added 0.04%	2,835 $184,000
Q4 2018 Feb 15, 2019	BUY	$60.54 - $79.0 $121 - $158	2 Added 0.07%	2,834 $177,000
Q3 2018 Oct 31, 2018	BUY	$71.28 - $78.92 $71 - $78	1 Added 0.04%	2,832 $219,000
Q2 2018 Jul 31, 2018	BUY	$64.88 - $75.68 $129 - $151	2 Added 0.07%	2,831 $201,000
Q1 2018 May 04, 2018	BUY	$72.84 - $88.8 $206,064 - $251,215	2,829 New	2,829 $213,000
Q4 2017 Feb 02, 2018	SELL	$71.15 - $83.52 $189,970 - $222,998	-2,670 Closed	0 $0
Q3 2017 Nov 01, 2017	BUY	$72.11 - $85.47 $192,533 - $228,204	2,670	2,670 $216,000

Others Institutions Holding GILD

# of Institutions

2,247

Shares Held

998M

Call Options Held

8.86M

Put Options Held

8.69M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $130B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bray Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Bray Capital Advisors with notifications on news.

Account

Bray Capital Advisors Gilead Sciences, Inc. Transaction History